Identification

Name
Hexobarbital
Accession Number
DB01355  (EXPT03301)
Type
Small Molecule
Groups
Approved
Description

A barbiturate that is effective as a hypnotic and sedative.

Structure
Thumb
Synonyms
  • 5-(1-cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione
  • 5-(1-cyclohexen-1-yl)-1,5-dimethylbarbituric acid
  • 5-Cyclohex-1-enyl-1,5-dimethyl-pyrimidine-2,4,6-trione
  • Hexobarbitone
  • Methexenyl
  • Methylhexabital
External IDs
NSC-71929
Product Ingredients
IngredientUNIICASInChI Key
Hexobarbital sodiumI788X867K750-09-9SQMCFUSVGSBKFK-UHFFFAOYSA-M
International/Other Brands
Citopan / Evipal / Evipan / Tobinal
Categories
UNII
AL8Z8K3P6S
CAS number
56-29-1
Weight
Average: 236.267
Monoisotopic: 236.116092388
Chemical Formula
C12H16N2O3
InChI Key
UYXAWHWODHRRMR-UHFFFAOYSA-N
InChI
InChI=1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)
IUPAC Name
5-(cyclohex-1-en-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione
SMILES
CN1C(=O)NC(=O)C(C)(C1=O)C1=CCCCC1

Pharmacology

Indication

For the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.

Structured Indications
Not Available
Pharmacodynamics

Hexobarbital is a barbiturate derivative having hypnotic and sedative effects. It was used in the 1940s-1950s as an agent for inducing anesthesia for surgery and has a relatively fast onset of effects and short duration of action. However it can be difficult to control the depth of anesthesia with hexobarbital which makes it quite dangerous, and it has now been replaced by safer drugs in human medicine, usually thiopental would be the barbiturate of choice for this application these days.

Mechanism of action

Hexobarbital binds at a distinct binding site associated with a Cl- ionopore at the GABA-A receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-4
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-5
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-6
potentiator
Human
UNeuronal acetylcholine receptor subunit alpha-4
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-7
antagonist
Human
UGlutamate receptor 2
antagonist
Human
UGlutamate receptor ionotropic, kainate 2
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

25%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of an overdose typically include sluggishness, incoordination, difficulty in thinking, slowness of speech, faulty judgment, drowsiness or coma, shallow breathing, staggering, and in severe cases coma and death.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Hexobarbital is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Hexobarbital can be increased when it is combined with Abiraterone.Approved
AcebutololHexobarbital may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Hexobarbital.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Hexobarbital.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Alaproclate.Experimental
AldesleukinHexobarbital may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Hexobarbital.Approved, Illicit
AliskirenHexobarbital may increase the hypotensive activities of Aliskiren.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Hexobarbital.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Hexobarbital.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Hexobarbital.Experimental, Investigational
AmifostineHexobarbital may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideHexobarbital may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Hexobarbital.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Hexobarbital.Approved
AmiodaroneThe metabolism of Hexobarbital can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Hexobarbital.Approved
AmlodipineHexobarbital may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Hexobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amperozide.Experimental
Amphotericin BHexobarbital may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmrinoneThe metabolism of Amrinone can be increased when combined with Hexobarbital.Approved
Amyl NitriteHexobarbital may increase the hypotensive activities of Amyl Nitrite.Approved
ApomorphineHexobarbital may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineHexobarbital may increase the hypotensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Hexobarbital can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Hexobarbital.Approved, Investigational
ArmodafinilThe metabolism of Hexobarbital can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Hexobarbital.Approved, Investigational
Arsenic trioxideHexobarbital may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Hexobarbital.Approved
AtazanavirThe metabolism of Hexobarbital can be decreased when combined with Atazanavir.Approved, Investigational
AtenololHexobarbital may increase the hypotensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Hexobarbital can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Azaperone.Investigational, Vet Approved
AzelastineHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Hexobarbital.Approved, Investigational
Azilsartan medoxomilHexobarbital may increase the hypotensive activities of Azilsartan medoxomil.Approved
AzimilideThe metabolism of Azimilide can be increased when combined with Hexobarbital.Investigational
AzithromycinThe metabolism of Hexobarbital can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Barbital.Illicit
BarnidipineThe metabolism of Barnidipine can be increased when combined with Hexobarbital.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Hexobarbital.Experimental
BenazeprilHexobarbital may increase the hypotensive activities of Benazepril.Approved, Investigational
BencyclaneThe metabolism of Bencyclane can be increased when combined with Hexobarbital.Experimental
BendroflumethiazideHexobarbital may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Hexobarbital.Approved, Investigational
BenperidolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Hexobarbital.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Benzyl alcohol.Approved
BepridilThe metabolism of Bepridil can be increased when combined with Hexobarbital.Approved, Withdrawn
BetaxololHexobarbital may increase the hypotensive activities of Betaxolol.Approved
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Hexobarbital.Approved
BisoprololHexobarbital may increase the hypotensive activities of Bisoprolol.Approved
BoceprevirThe metabolism of Hexobarbital can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Hexobarbital.Approved
BortezomibThe metabolism of Hexobarbital can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Hexobarbital can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumHexobarbital may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Hexobarbital.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Bromisoval.Experimental
BromocriptineHexobarbital may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Hexobarbital.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Hexobarbital.Experimental, Investigational
BumetanideHexobarbital may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Hexobarbital.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Hexobarbital.Approved
BuprenorphineHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Hexobarbital.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Hexobarbital.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Hexobarbital.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hexobarbital.Approved, Illicit, Vet Approved
CaffeineThe metabolism of Hexobarbital can be decreased when combined with Caffeine.Approved
CanagliflozinHexobarbital may increase the hypotensive activities of Canagliflozin.Approved
Candesartan cilexetilHexobarbital may increase the hypotensive activities of Candesartan.Approved
CanertinibThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Canertinib.Investigational
CapecitabineThe metabolism of Hexobarbital can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilHexobarbital may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Hexobarbital can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinHexobarbital may increase the hypotensive activities of Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Carbinoxamine.Approved
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be increased when combined with Hexobarbital.Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Carisoprodol.Approved
CaroverineThe metabolism of Caroverine can be increased when combined with Hexobarbital.Experimental
CarteololHexobarbital may increase the hypotensive activities of Carteolol.Approved
CarvedilolHexobarbital may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Hexobarbital.Approved, Investigational
CeritinibThe serum concentration of Hexobarbital can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Hexobarbital can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Hexobarbital.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Hexobarbital.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Hexobarbital.Approved
ChlorothiazideHexobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Hexobarbital.Investigational, Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Hexobarbital.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Hexobarbital.Approved, Investigational, Withdrawn
ChlorthalidoneHexobarbital may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Hexobarbital can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilHexobarbital may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Hexobarbital.Approved, Investigational
CimetidineThe metabolism of Hexobarbital can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Hexobarbital.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Hexobarbital.Approved, Investigational
CitalopramThe metabolism of Hexobarbital can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Hexobarbital can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Hexobarbital can be decreased when combined with Clemastine.Approved
ClevidipineHexobarbital may increase the hypotensive activities of Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clobazam.Approved, Illicit
ClofarabineHexobarbital may increase the hypotensive activities of Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Hexobarbital is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Hexobarbital.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clopenthixol.Experimental
CloranololThe serum concentration of Cloranolol can be decreased when it is combined with Hexobarbital.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Hexobarbital.Approved, Illicit
ClorindioneThe metabolism of Clorindione can be increased when combined with Hexobarbital.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Hexobarbital can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Hexobarbital.Approved
CobicistatThe metabolism of Hexobarbital can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Hexobarbital.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Hexobarbital.Approved, Illicit
ConivaptanThe serum concentration of Hexobarbital can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe therapeutic efficacy of Conjugated estrogens can be decreased when used in combination with Hexobarbital.Approved
CrisaboroleThe metabolism of Hexobarbital can be decreased when combined with Crisaborole.Approved
CrizotinibThe metabolism of Hexobarbital can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Hexobarbital.Approved
CyclopenthiazideHexobarbital may increase the orthostatic hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Hexobarbital.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Hexobarbital can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Hexobarbital can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dantrolene.Approved
DapagliflozinHexobarbital may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Hexobarbital.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dapoxetine.Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Hexobarbital.Experimental
DarunavirThe metabolism of Hexobarbital can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Hexobarbital can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Hexobarbital can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Hexobarbital can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Hexobarbital.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Hexobarbital.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Desloratadine.Approved, Investigational
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Hexobarbital.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hexobarbital.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hexobarbital.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Hexobarbital.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Hexobarbital.Approved, Illicit, Vet Approved
DibenzepinThe metabolism of Dibenzepin can be increased when combined with Hexobarbital.Experimental
DiclofenamideHexobarbital may increase the hypotensive activities of Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Hexobarbital.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Hexobarbital.Approved, Investigational
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Hexobarbital.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Diethyl ether.Experimental
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Hexobarbital.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hexobarbital.Approved, Illicit
DihydroergotamineThe metabolism of Hexobarbital can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Hexobarbital can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dimenhydrinate.Approved
DinutuximabHexobarbital may increase the hypotensive activities of Dinutuximab.Approved
DiphenadioneThe metabolism of Diphenadione can be increased when combined with Hexobarbital.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Hexobarbital.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hexobarbital.Approved, Illicit
DipyridamoleHexobarbital may increase the hypotensive activities of Dipyridamole.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Hexobarbital.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Hexobarbital.Investigational
DoxazosinHexobarbital may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Hexobarbital.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Hexobarbital.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Hexobarbital is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved, Illicit
DronedaroneThe metabolism of Hexobarbital can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Hexobarbital.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Hexobarbital.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Hexobarbital.Approved
EcgonineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Efavirenz.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be increased when combined with Hexobarbital.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Eltanolone.Investigational
EmpagliflozinHexobarbital may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilHexobarbital may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatHexobarbital may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Hexobarbital.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Hexobarbital can be decreased when it is combined with Enzalutamide.Approved
EpanololThe serum concentration of Epanolol can be decreased when it is combined with Hexobarbital.Experimental
EperisoneThe metabolism of Eperisone can be increased when combined with Hexobarbital.Approved, Investigational
EplerenoneHexobarbital may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolHexobarbital may increase the hypotensive activities of Epoprostenol.Approved
EprosartanHexobarbital may increase the hypotensive activities of Eprosartan.Approved
ErythromycinThe metabolism of Hexobarbital can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Hexobarbital can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Hexobarbital.Investigational
EsmololHexobarbital may increase the hypotensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Hexobarbital can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Hexobarbital.Approved, Illicit
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Hexobarbital.Approved, Investigational, Vet Approved
EstramustineThe therapeutic efficacy of Estramustine can be decreased when used in combination with Hexobarbital.Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Hexobarbital.Approved
Estrone sulfateThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Hexobarbital.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Hexobarbital.Approved
Etacrynic acidHexobarbital may increase the hypotensive activities of Etacrynic acid.Approved
EthanolHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Hexobarbital.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Hexobarbital.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethotoin.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Hexobarbital.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Hexobarbital.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Hexobarbital.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Hexobarbital.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Hexobarbital can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ezogabine.Approved
FelbamateThe serum concentration of Hexobarbital can be increased when it is combined with Felbamate.Approved
FelodipineHexobarbital may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Hexobarbital.Withdrawn
FenoldopamHexobarbital may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hexobarbital.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fexofenadine.Approved
FimasartanHexobarbital may increase the hypotensive activities of Fimasartan.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Flibanserin.Approved
FloxuridineThe metabolism of Hexobarbital can be decreased when combined with Floxuridine.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Hexobarbital can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fludiazepam.Approved, Illicit
FluindioneThe metabolism of Fluindione can be increased when combined with Hexobarbital.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Hexobarbital can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Hexobarbital can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Hexobarbital.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Hexobarbital.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Hexobarbital.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fluticasone propionate.Approved
FluvastatinThe metabolism of Hexobarbital can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Hexobarbital can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Hexobarbital can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Hexobarbital can be increased when it is combined with Fosaprepitant.Approved
FosinoprilHexobarbital may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe metabolism of Hexobarbital can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Fospropofol.Approved, Illicit, Investigational
FurosemideHexobarbital may increase the hypotensive activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Hexobarbital can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Hexobarbital.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Gabapentin Enacarbil.Approved
GallopamilThe metabolism of Gallopamil can be increased when combined with Hexobarbital.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Hexobarbital.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Hexobarbital can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Hexobarbital.Approved, Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Glutethimide.Approved, Illicit
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Hexobarbital.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Hexobarbital.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Hexobarbital.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Hexobarbital.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Heroin.Approved, Illicit, Investigational
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Hexobarbital.Withdrawn
HydralazineHexobarbital may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideHexobarbital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideHexobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hexobarbital.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
IdelalisibThe serum concentration of Hexobarbital can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Iloperidone.Approved
IloprostHexobarbital may increase the hypotensive activities of Iloprost.Approved, Investigational
ImatinibThe metabolism of Hexobarbital can be decreased when combined with Imatinib.Approved
ImidaprilHexobarbital may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Hexobarbital.Approved
IndalpineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Indalpine.Investigational, Withdrawn
IndapamideHexobarbital may increase the orthostatic hypotensive activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Hexobarbital.Withdrawn
IndinavirThe metabolism of Hexobarbital can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Indiplon.Investigational
IndoraminHexobarbital may increase the hypotensive activities of Indoramin.Withdrawn
IprindoleThe metabolism of Iprindole can be increased when combined with Hexobarbital.Experimental
IrbesartanThe metabolism of Hexobarbital can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Hexobarbital can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidHexobarbital may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Hexobarbital.Approved, Vet Approved
IsoniazidThe metabolism of Hexobarbital can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateHexobarbital may increase the hypotensive activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateHexobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineHexobarbital may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe metabolism of Hexobarbital can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Hexobarbital can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Hexobarbital can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Hexobarbital.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Hexobarbital can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolHexobarbital may increase the hypotensive activities of Labetalol.Approved
LacidipineThe metabolism of Lacidipine can be increased when combined with Hexobarbital.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Hexobarbital.Approved, Investigational
LandiololThe serum concentration of Landiolol can be decreased when it is combined with Hexobarbital.Investigational
LeflunomideThe metabolism of Hexobarbital can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Hexobarbital.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levetiracetam.Approved, Investigational
LevobunololHexobarbital may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Hexobarbital.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hexobarbital.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Levomilnacipran.Approved
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Hexobarbital.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hexobarbital.Approved
LevosimendanHexobarbital may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidocaineThe metabolism of Hexobarbital can be decreased when combined with Lidocaine.Approved, Vet Approved
LidoflazineThe metabolism of Lidoflazine can be increased when combined with Hexobarbital.Experimental
LisinoprilHexobarbital may increase the hypotensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lithium.Approved
LobeglitazoneThe metabolism of Hexobarbital can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lofentanil.Illicit
LofepramineThe metabolism of Lofepramine can be increased when combined with Hexobarbital.Experimental
LofexidineHexobarbital may increase the hypotensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Hexobarbital can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Hexobarbital.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Lormetazepam.Approved
LosartanThe metabolism of Hexobarbital can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Hexobarbital can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Hexobarbital.Approved
LuliconazoleThe serum concentration of Hexobarbital can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Hexobarbital can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Hexobarbital.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Hexobarbital.Investigational
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved, Vet Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Hexobarbital.Approved, Investigational
MannitolHexobarbital may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Mebicar.Experimental
MecamylamineHexobarbital may increase the hypotensive activities of Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Hexobarbital.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Hexobarbital.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Melperone.Approved, Investigational
MepindololThe serum concentration of Mepindolol can be decreased when it is combined with Hexobarbital.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Hexobarbital.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Hexobarbital.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Hexobarbital.Approved, Investigational
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Hexobarbital.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Hexobarbital.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methadyl Acetate.Approved, Illicit
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Hexobarbital.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methaqualone.Illicit, Withdrawn
MethazolamideHexobarbital may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Hexobarbital.Approved
MethotrimeprazineHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Hexobarbital.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methsuximide.Approved
MethyclothiazideHexobarbital may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaHexobarbital may increase the hypotensive activities of Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Hexobarbital.Approved
MetipranololHexobarbital may increase the hypotensive activities of Metipranolol.Approved
MetolazoneHexobarbital may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololHexobarbital may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineHexobarbital may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Hexobarbital can be decreased when combined with Mexiletine.Approved
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be increased when combined with Hexobarbital.Investigational, Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Hexobarbital.Approved, Illicit
MidostaurinThe metabolism of Hexobarbital can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Hexobarbital can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved, Investigational
MinoxidilHexobarbital may increase the hypotensive activities of Minoxidil.Approved
MirtazapineHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Hexobarbital can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Hexobarbital can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Hexobarbital can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilHexobarbital may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Hexobarbital.Approved, Investigational
MoxonidineHexobarbital may increase the hypotensive activities of Moxonidine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved, Investigational
NadololHexobarbital may increase the hypotensive activities of Nadolol.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Hexobarbital.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hexobarbital.Approved
NebivololHexobarbital may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Hexobarbital can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Hexobarbital can be decreased when combined with Nelfinavir.Approved
NesiritideHexobarbital may increase the hypotensive activities of Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Hexobarbital can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Hexobarbital can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Hexobarbital can be decreased when combined with Nicardipine.Approved
NifedipineHexobarbital may increase the hypotensive activities of Nifedipine.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Hexobarbital.Experimental
NilotinibThe metabolism of Hexobarbital can be decreased when combined with Nilotinib.Approved, Investigational
NiludipineThe metabolism of Niludipine can be increased when combined with Hexobarbital.Experimental
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Hexobarbital.Approved, Investigational
NimesulideThe metabolism of Nimesulide can be increased when combined with Hexobarbital.Approved, Investigational, Withdrawn
NimodipineHexobarbital may increase the hypotensive activities of Nimodipine.Approved
NisoldipineHexobarbital may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Hexobarbital.Approved
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Hexobarbital.Approved, Investigational
Nitric OxideHexobarbital may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinHexobarbital may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideHexobarbital may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Hexobarbital.Approved, Vet Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Hexobarbital.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Norflurane.Investigational
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Hexobarbital.Approved
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Hexobarbital.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Hexobarbital.Approved
ObinutuzumabHexobarbital may increase the hypotensive activities of Obinutuzumab.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Hexobarbital.Approved, Investigational
OlaparibThe metabolism of Hexobarbital can be decreased when combined with Olaparib.Approved
OlmesartanHexobarbital may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Hexobarbital can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Hexobarbital.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Hexobarbital.Investigational
OpiumThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Opium.Approved, Illicit
OrphenadrineHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Hexobarbital can be increased when it is combined with Osimertinib.Approved
OtiloniumThe metabolism of Otilonium can be increased when combined with Hexobarbital.Experimental, Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Hexobarbital.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Hexobarbital.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hexobarbital.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hexobarbital.Approved, Investigational, Vet Approved
PaclitaxelHexobarbital may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Hexobarbital can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Hexobarbital.Approved
PantoprazoleThe metabolism of Hexobarbital can be decreased when combined with Pantoprazole.Approved
PapaverineHexobarbital may increase the hypotensive activities of Papaverine.Approved
ParaldehydeHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Hexobarbital can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololHexobarbital may increase the hypotensive activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hexobarbital.Approved, Vet Approved
PentobarbitalThe metabolism of Hexobarbital can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
PerazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Perazine.Investigational
PerhexilineThe metabolism of Perhexiline can be increased when combined with Hexobarbital.Approved, Investigational
PerindoprilHexobarbital may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Hexobarbital.Approved
PethidineHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Phenazocine.Experimental
PhenelzineHexobarbital may increase the hypotensive activities of Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Phenibut.Experimental
PhenindioneThe metabolism of Phenindione can be increased when combined with Hexobarbital.Approved, Investigational
PhenobarbitalThe metabolism of Hexobarbital can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Phenoperidine.Experimental
PhenoxybenzamineHexobarbital may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Hexobarbital.Approved, Investigational
PhentolamineHexobarbital may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe metabolism of Hexobarbital can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Hexobarbital.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Hexobarbital.Approved
PindololHexobarbital may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pizotifen.Approved
PolythiazideHexobarbital may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Hexobarbital can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Hexobarbital.Approved
PramipexoleHexobarbital may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Prazepam.Approved, Illicit
PrazosinHexobarbital may increase the hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Hexobarbital.Approved, Illicit, Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Hexobarbital.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Hexobarbital.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Hexobarbital.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Hexobarbital.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hexobarbital.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Hexobarbital.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Promethazine.Approved
PropacetamolThe metabolism of Propacetamol can be increased when combined with Hexobarbital.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Hexobarbital.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Hexobarbital.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Propoxycaine.Approved
PropranololHexobarbital may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Hexobarbital.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Hexobarbital is combined with PSD502.Investigational
PyridoxineThe metabolism of Hexobarbital can be increased when combined with Pyridoxine.Approved, Nutraceutical, Vet Approved
PyrimethamineThe metabolism of Hexobarbital can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Hexobarbital.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Hexobarbital.Approved
QuinaprilHexobarbital may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneHexobarbital may increase the orthostatic hypotensive activities of Quinethazone.Approved
QuinineThe metabolism of Hexobarbital can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ramelteon.Approved, Investigational
RamiprilHexobarbital may increase the hypotensive activities of Ramipril.Approved
RanolazineThe metabolism of Hexobarbital can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineHexobarbital may increase the hypotensive activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hexobarbital.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Hexobarbital.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Hexobarbital.Approved, Investigational
RifabutinThe metabolism of Hexobarbital can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Hexobarbital can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Hexobarbital can be increased when combined with Rifapentine.Approved
RiociguatHexobarbital may increase the hypotensive activities of Riociguat.Approved
RisedronateThe metabolism of Risedronate can be increased when combined with Hexobarbital.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Hexobarbital.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ritanserin.Investigational
RitonavirThe metabolism of Hexobarbital can be decreased when combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Romifidine.Vet Approved
RopiniroleHexobarbital may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Hexobarbital.Approved
RotigotineHexobarbital may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Hexobarbital.Approved
SacubitrilHexobarbital may increase the hypotensive activities of Sacubitril.Approved
SaquinavirThe metabolism of Hexobarbital can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Hexobarbital can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineHexobarbital may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Hexobarbital can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Hexobarbital.Approved, Vet Approved
SildenafilThe metabolism of Hexobarbital can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Hexobarbital can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Hexobarbital can be increased when it is combined with Simeprevir.Approved
Sodium NitriteHexobarbital may increase the hypotensive activities of Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Hexobarbital.Approved, Investigational
SorafenibThe metabolism of Hexobarbital can be decreased when combined with Sorafenib.Approved, Investigational
SotalolHexobarbital may increase the hypotensive activities of Sotalol.Approved
SpironolactoneHexobarbital may increase the hypotensive activities of Spironolactone.Approved
St. John's WortThe serum concentration of Hexobarbital can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Hexobarbital can be increased when it is combined with Stiripentol.Approved
StreptokinaseHexobarbital may increase the hypotensive activities of Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hexobarbital.Approved, Investigational
SulfadiazineThe metabolism of Hexobarbital can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Hexobarbital can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Hexobarbital can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Hexobarbital.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Sultopride.Experimental
SuvorexantHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Hexobarbital.Approved
TalinololThe serum concentration of Talinolol can be decreased when it is combined with Hexobarbital.Investigational
TamsulosinHexobarbital may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Hexobarbital can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Hexobarbital can be decreased when combined with Telithromycin.Approved
TelmisartanHexobarbital may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Hexobarbital.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Hexobarbital.Approved
Tenofovir disoproxilThe metabolism of Hexobarbital can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerazosinHexobarbital may increase the hypotensive activities of Terazosin.Approved
TeriflunomideThe serum concentration of Hexobarbital can be decreased when it is combined with Teriflunomide.Approved
TerodilineThe metabolism of Terodiline can be increased when combined with Hexobarbital.Experimental
TertatololThe serum concentration of Tertatolol can be decreased when it is combined with Hexobarbital.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tetrodotoxin.Investigational
ThalidomideHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Hexobarbital can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Hexobarbital.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Hexobarbital.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Hexobarbital.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Hexobarbital.Approved
TiagabineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tiagabine.Approved
TianeptineThe metabolism of Tianeptine can be increased when combined with Hexobarbital.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Hexobarbital can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Hexobarbital can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tilidine.Experimental
TimololHexobarbital may increase the hypotensive activities of Timolol.Approved
TioclomarolThe metabolism of Tioclomarol can be increased when combined with Hexobarbital.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Hexobarbital can be decreased when it is combined with Tocilizumab.Approved
TolazolineHexobarbital may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Hexobarbital can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Hexobarbital.Approved
TopiramateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Topiramate.Approved
TopiroxostatThe metabolism of Hexobarbital can be decreased when combined with Topiroxostat.Approved, Investigational
TorasemideHexobarbital may increase the hypotensive activities of Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Hexobarbital.Approved, Investigational
TrandolaprilHexobarbital may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Hexobarbital.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Hexobarbital.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Hexobarbital.Approved, Investigational
TretinoinHexobarbital may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneHexobarbital may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Hexobarbital.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Tricaine methanesulfonate.Vet Approved
TrichlormethiazideHexobarbital may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Hexobarbital.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Hexobarbital.Approved, Vet Approved
TrimethoprimThe metabolism of Hexobarbital can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Hexobarbital.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Triprolidine.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Hexobarbital.Approved
Valproic AcidThe serum concentration of Hexobarbital can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Hexobarbital can be decreased when combined with Valsartan.Approved, Investigational
VemurafenibThe serum concentration of Hexobarbital can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Hexobarbital can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Veralipride.Experimental
VerapamilThe metabolism of Hexobarbital can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Vigabatrin.Approved
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Hexobarbital.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Vinyl ether.Experimental
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Hexobarbital.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Vortioxetine.Approved
WarfarinThe metabolism of Warfarin can be increased when combined with Hexobarbital.Approved
XenonThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Xylazine.Vet Approved
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Hexobarbital.Approved
ZafirlukastThe metabolism of Hexobarbital can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Hexobarbital.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Hexobarbital can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zolazepam.Vet Approved
ZolpidemHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Hexobarbital.Approved
ZotepineThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Zotepine.Approved, Investigational
ZucapsaicinThe metabolism of Hexobarbital can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Hexobarbital.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Takenoshita R, Toki S: [New aspects of hexobarbital metabolism: stereoselective metabolism, new metabolic pathway via GSH conjugation, and 3-hydroxyhexobarbital dehydrogenases]. Yakugaku Zasshi. 2004 Dec;124(12):857-71. [PubMed:15577260]
  2. Wahlstrom G: A study of the duration of acute tolerance induced with hexobarbital in male rats. Pharmacol Biochem Behav. 1998 Apr;59(4):945-8. [PubMed:9586853]
  3. Korkmaz S, Ljungblad E, Wahlstrom G: Interaction between flumazenil and the anesthetic effects of hexobarbital in the rat. Brain Res. 1995 Apr 10;676(2):371-7. [PubMed:7614008]
  4. Dall V, Orntoft U, Schmidt A, Nordholm L: Interaction of the competitive AMPA receptor antagonist NBQX with hexobarbital. Pharmacol Biochem Behav. 1993 Sep;46(1):73-6. [PubMed:8255925]
External Links
Human Metabolome Database
HMDB15444
KEGG Drug
D01071
KEGG Compound
C11723
PubChem Compound
3608
PubChem Substance
46508777
ChemSpider
3482
ChEBI
5706
ChEMBL
CHEMBL7728
Therapeutic Targets Database
DAP000688
PharmGKB
PA449875
Wikipedia
Hexobarbital
ATC Codes
N01AF02 — HexobarbitalN05CA16 — HexobarbitalN05CB01 — Combinations of barbiturates

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)146.5 °CPhysProp
water solubility435 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.98SANGSTER (1994)
logS-2.74ADME Research, USCD
pKa8.2SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility1.51 mg/mLALOGPS
logP1.8ALOGPS
logP1.25ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)8.41ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area66.48 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity61.95 m3·mol-1ChemAxon
Polarizability24.14 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9793
Blood Brain Barrier+0.9649
Caco-2 permeable+0.519
P-glycoprotein substrateSubstrate0.5562
P-glycoprotein inhibitor IInhibitor0.7705
P-glycoprotein inhibitor IINon-inhibitor0.8379
Renal organic cation transporterNon-inhibitor0.7687
CYP450 2C9 substrateNon-substrate0.7622
CYP450 2D6 substrateNon-substrate0.894
CYP450 3A4 substrateNon-substrate0.543
CYP450 1A2 substrateNon-inhibitor0.7994
CYP450 2C9 inhibitorInhibitor0.5316
CYP450 2D6 inhibitorNon-inhibitor0.9369
CYP450 2C19 inhibitorNon-inhibitor0.6349
CYP450 3A4 inhibitorNon-inhibitor0.9571
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8803
Ames testNon AMES toxic0.7061
CarcinogenicityNon-carcinogens0.8753
BiodegradationNot ready biodegradable0.9143
Rat acute toxicity2.5050 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9348
hERG inhibition (predictor II)Non-inhibitor0.8502
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.16 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00gi-9420000000-001b8f1462933b4fb9c1
Mass Spectrum (Electron Ionization)MSsplash10-05cu-9310000000-eeec363075c613d35696
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Pyrimidones
Alternative Parents
Hydropyrimidines / Dicarboximides / Organic carbonic acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Pyrimidone / Hydropyrimidine / 1,2,5,6-tetrahydropyrimidine / Dicarboximide / Carbonic acid derivative / Azacycle / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Carboxylic acid derivative / Organic oxide
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
barbiturates (CHEBI:5706)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
  3. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  4. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
  5. Tomlin SL, Jenkins A, Lieb WR, Franks NP: Preparation of barbiturate optical isomers and their effects on GABA(A) receptors. Anesthesiology. 1999 Jun;90(6):1714-22. [PubMed:10360871]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  8. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA4
Uniprot ID
P48169
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-4
Molecular Weight
61622.645 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA6
Uniprot ID
Q16445
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-6
Molecular Weight
51023.69 Da
References
  1. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232]
  2. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Toxic substance binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
Gene Name
CHRNA7
Uniprot ID
P36544
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-7
Molecular Weight
56448.925 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Arias HR, Bhumireddy P: Anesthetics as chemical tools to study the structure and function of nicotinic acetylcholine receptors. Curr Protein Pept Sci. 2005 Oct;6(5):451-72. [PubMed:16248797]
  3. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Ionotropic glutamate receptor activity
Specific Function
Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system and plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory ne...
Gene Name
GRIA2
Uniprot ID
P42262
Uniprot Name
Glutamate receptor 2
Molecular Weight
98820.32 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Kainate selective glutamate receptor activity
Specific Function
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a co...
Gene Name
GRIK2
Uniprot ID
Q13002
Uniprot Name
Glutamate receptor ionotropic, kainate 2
Molecular Weight
102582.475 Da
References
  1. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449]
  2. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Adedoyin A, Prakash C, O'Shea D, Blair IA, Wilkinson GR: Stereoselective disposition of hexobarbital and its metabolites: relationship to the S-mephenytoin polymorphism in Caucasian and Chinese subjects. Pharmacogenetics. 1994 Feb;4(1):27-38. [PubMed:8004130]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Lewis DF, Modi S, Dickins M: Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82. [PubMed:11996013]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M: Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica. 1996 Jul;26(7):681-93. [PubMed:8819299]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 02:59